Flash20 Rapid PCR System Enables 30-Minute Detection of Fever Patients, Supporting Precision Pandemic Control at Beijing Tsinghua Changgeng Hospital

According to the official announcement from the Beijing Municipal Health Commission, on January 9, Beijing reported one new locally transmitted confirmed case of COVID-19. The patient tested positive for the novel coronavirus while seeking medical care proactively. The confirmed case currently resides in Lianzhuang Village, Zhaoquanying Town, Shunyi District.On January 8, the patient visited the fever clinic of Beijing Tsinghua Changgung Hospital. After undergoing a rapid nucleic acid test for COVID-19, the result returned positive two hours later., chest CT indicated pulmonary inflammation. Based on a comprehensive assessment of epidemiological history, clinical manifestations, laboratory tests, and imaging findings, the case was diagnosed as confirmed on January 9 and classified as moderate in severity. The confirmed case was promptly transferred to Ditan Hospital for treatment.

Rapid and precise diagnosis of suspected cases, particularly asymptomatic carriers, to enable swift screening and triage, cut off transmission sources, and prevent cross-infection is key to controlling the epidemic.

Tsinghua Changgung Hospital Uses Cayody Flash TestFlash20 Positive patients detected by the rapid nucleic acid testing system,On-machine testing takes only 30 minutes.The detection of a positive result enabled rapid and accurate screening of the febrile patient, significantly mitigating the risk of transmission due to crowd aggregation within the hospital.

Since the outbreak of the COVID-19 pandemic in early 2020, to improve testing efficiency, Kayoudi has successfully developed the Flash20 Rapid Nucleic Acid Testing System for SARS-CoV-2, leveraging its extensive technological reserves accumulated over many years. This system features a simplified pre-processing workflow, requiring only one minute of manual operation at most, with test results available within 30 minutes after loading onto the instrument. By adopting an independent temperature control mode for each reaction chamber, the system breaks away from the traditional practice of batch sample processing, enabling on-demand testing as samples arrive. This addresses the limitations of existing nucleic acid testing technologies in terms of efficiency. Validated through extensive clinical real-world samples, the system demonstrates both sensitivity and specificity exceeding 95%, with a limit of detection (LOD) of 400 copies/mL, comparable to high-throughput conventional nucleic acid testing systems. In the context of normalized pandemic management, it ensures that nucleic acid testing reports can be issued within one hour across various emergency scenarios.

Currently, products from the domestic brand Cayody have garnered significant attention and acclaim within the industry. Driven by its vision of “making molecular diagnostics accessible to all,” Cayody continues to pioneer innovations across diverse fields, including epidemic prevention and control, healthcare, food safety, and basic scientific research. The company is committed to providing nucleic acid testing solutions that are affordable, high-quality, and readily available for China’s epidemic response efforts.

Cayody Biotechnology (Beijing) Co., Ltd. is a Chinese high-tech innovation enterprise with independent original R&D capabilities, having dedicated itself to the field of molecular diagnostics for 10 years. The company specializes in rapid nucleic acid detection technologies for pathogenic microorganisms. It possesses the capability for cross-disciplinary joint development across instruments, reagents, system platforms, and AI-driven big data, and holds core technologies with independent intellectual property rights.

Founded in 2009, the company is headquartered in Beijing, where its R&D center is also located, and operates an 8,000-square-meter GMP-compliant production base in Yixing, Jiangsu Province. As a national high-tech enterprise and an academician expert workstation, it has been honored with prestigious awards such as “Top 50 Most Investable Companies in China” and “China’s Most Promising Companies.” It has successfully secured investments from numerous renowned venture capital firms, including Hillhouse Capital, Northern Light Venture Capital, SAIF Partners, and Legend Star.

Caydee Bio Official Website:http://www.coyotebio.com